Needham analyst Serge Belanger has maintained their bullish stance on LQDA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors that highlight the positive outlook for Liquidia Technologies. A recent court decision in favor of Liquidia has removed the final legal obstacle that could have delayed the FDA approval of their product, Yutrepia. This development is crucial as it clears the path for the anticipated approval of Yutrepia, which is expected to occur once the exclusivity period for a competing product, Tyvaso, ends in May 2025.
Belanger’s confidence in Liquidia’s prospects is further bolstered by the expected FDA approval for Yutrepia, which targets conditions such as PAH and PH-ILD. The removal of legal barriers and the upcoming expiration of Tyvaso’s exclusivity provide a favorable environment for Liquidia to capitalize on its market opportunities. These factors collectively contribute to the Buy rating, indicating a positive future performance for the company’s stock.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $35.00 price target.